Biomaterial and method for promoting tissue regeneration by using the biomaterial

Abstract

The present disclosure provides a biomaterial and a method for promoting tissue regeneration by using the biomaterial.

Claims

1. A biomaterial for promoting regeneration of bone tissues, consisting of a biocompatible polymer, an inorganic salt, a cross-linking agent, and a hypoglycemic drug; wherein the inorganic salt is dicalcium phosphate (DCP) or dicalcium phosphate dihydrate (DCPD); wherein the biocompatible polymer is in a form of a sphere or a film; wherein the cross-linking agent is selected from the group consisting of lipase, peptidase, sortase, oxidoreductase, polyphenoloxidase (PPO), lysyl oxidase, and amine oxidase; wherein promotion of regeneration of bone tissues is essentially from the hypoglycemic drug; wherein the biocompatible polymer is alginate.

2. The biomaterial according to claim 1, wherein the hypoglycemic drug is selected from the group consisting of biguanide, insulin, sulfonylurea, meglitinide, thiazolidinedione, an α-glucosidase inhibitor, a dipeptidyl peptidase 4 (DPP-4) inhibitor, a sodium-glucose transport protein 2 (SGLT2) inhibitor, and bromocriptine.

3. The biomaterial according to claim 2, wherein the biguanide is metformin.

4. The biomaterial according to claim 2, wherein the Sulfonylurea is selected from the group consisting of glipizide, glyburide, gliclazide, and glimepiride.

5. The biomaterial according to claim 2, wherein the meglitinide is a repaglinide or a nateglinide.

6. The biomaterial according to claim 2, wherein the thiazolidinedione is a rosiglitazone or a pioglitazone.

7. The biomaterial according to claim 2, wherein the α-Glucosidase inhibitor is selected from the group consisting of acarbose, miglitol, and voglibose.

8. The biomaterial according to claim 2, wherein the DPP-4 inhibitor is selected from the group consisting of sitagliptin, saxagliptin, vildagliptin, linagliptin, and alogliptin.

9. The biomaterial according to claim 2, wherein the SGLT2 inhibitor is a dapagliflozin or a canagliflozin.

10. The biomaterial according to claim 1, wherein the biocompatible polymer has a concentration of 1-50% (w/v), the inorganic salt has a concentration of 1-50% (w/v), the hypoglycemic drug has a concentration of 1 nM-1 M, and the cross-linking agent has a concentration of 1-50 wt %.

11. The biomaterial according to claim 1, wherein the biocompatible polymer or the inorganic salt has an average size from 1 nm to 1 mm.

12. A method for promoting tissue regeneration, comprising administering to a subject in need thereof the biomaterial according to claim 1.

13. The method according to claim 12, wherein the biocompatible polymer has a concentration of 1-50% (w/v), the inorganic salt has a concentration of 1-50% (w/v), the hypoglycemic drug has a concentration of 1 nM-1 M, and the cross-linking agent has a concentration of 1-50 wt %.

Description

BRIEF DESCRIPTION OF THE DRAWINGS

(1) The following drawings form part of the present specification and are included here to further demonstrate some aspects of the present invention, which can be better understood by reference to one or more of these drawings, in combination with the detailed description of the embodiments presented herein.

(2) FIG. 1 is a microstructure diagram of a biomaterial of the present invention.

(3) FIG. 2 is a data diagram showing the effect of the biomaterial of the present invention (using insulin as a hypoglycemic drug component) on regulating osteoblast-specific genes on the 7th, 14th, 21th, and 28th days after treating cells.

(4) FIG. 3 is a computed tomography diagram showing the effect of the biomaterial of the present invention on promoting regeneration of bone tissues.

DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENT

(5) In the following detailed description of the embodiments of the present invention, reference is made to the accompanying drawings, which are shown to illustrate the specific embodiments in which the present disclosure may be practiced. These embodiments are provided to enable those skilled in the art to practice the present disclosure. It is understood that other embodiments may be used and that changes can be made to the embodiments without departing from the scope of the present invention. The following description is therefore not to be considered as limiting the scope of the present invention.

Definition

(6) As used herein, the data provided represent experimental values that can vary within a range of ±20%, preferably within ±10%, and most preferably within ±5%.

(7) Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which the present invention belongs. As used herein, the following terms have the following meanings.

(8) Unless specified otherwise in the context, the singular forms “a”, “an”, and “the” described herein and in claims include plural referents. The terms such as “a”, “the”, “one or more”, “plurality” and “at least one” are interchangeable.

(9) The terms “comprising”, “including”, “containing”, and “having” described herein may also be interchangeable without limitation.

(10) In addition, the term “and/or” is used herein to specifically express one or both of two particular features or compositions. Therefore, the term “and/or” is used to express a sentence such as “A and/or B” including “A and B”, “A or B”, “(individual) A”, and “(individual) B”. Similarly, the term “and/or” is used to express a sentence such as “A, B, and/or C” which includes the meanings described below: A, B and C; A, B or C; A or C; A or B; B or C; A and C; A and B; B and C; (individual) A; (individual) B; (individual) C.

(11) According to the present invention, the data show 4 independent experiments as mean±SD.

(12) As used herein, “hyperglycemic drugs” refer to clinically available hypoglycemic drugs, including, but not limited to, biguanide, insulin, sulfonylurea, meglitinide, thiazolidinedione, an α-Glucosidase inhibitor, a dipeptidyl peptidase 4 (DPP-4) inhibitor, a sodium-glucose transport protein 2 (SGLT2) inhibitor, and cycloset.

(13) According to the present invention, the biguanide is metformin; the sulfonylurea is selected from the group consisting of: glipizide, glyburide, gliclazide, and glimepiride; the meglitinide is a repaglinide or a nateglinide; the thiazolidinedione is a rosiglitazone or a pioglitazone; the α-Glucosidase inhibitor is selected from the group consisting of: acarbose, miglitol, and voglibose; the DPP-4 inhibitor is selected from the group consisting of: sitagliptin, saxagliptin, vildagliptin, linagliptin, and alogliptin; the SGLT2 inhibitor is a dapagliflozin or a canagliflozin; the cycloset is a bromocriptine.

(14) According to the present invention, the hypoglycemic drug has a concentration of 1 nM-1 M. Preferably, the hypoglycemic drug has a concentration of 1 μM-mM. More preferably, the hypoglycemic drug has a concentration of 10 μM-100 μM.

(15) The hypoglycemic drug referred to herein is a drug that is dissolved in a solvent. The solvent may be any polar or non-polar solvent. In a preferred embodiment, the polar solvent is water.

(16) According to the present invention, the biomaterial can be prepared as a medicament. The medicament can be manufactured to a form suitable for parenteral, oral or topical administration, using techniques well known to those skilled in the art, including, but not limited to, injection (e.g., sterile aqueous solution or dispersion), sterile powder, tablet, troche, lozenge, pill, capsule, dispersible powder or granule, solution, suspension, emulsion, syrup, elixir, slurry, external preparation, and the like.

(17) According to the present invention, the medicament may further comprise a pharmaceutically acceptable carrier which is widely used in pharmaceutically manufacturing techniques. For example, the pharmaceutically acceptable carrier can comprise one or more reagents selected from the group consisting of solvent, buffer, emulsifier, suspending agent, decomposer, disintegrating agent, dispersing agent, binding agent, excipient, stabilizing agent, chelating agent, diluent, gelling agent, preservative, wetting agent, lubricant, absorption delaying agent, liposome, and the like. The selection and quantity of these reagents fall within the scope of the professional literacy and routine techniques of those skilled in the art.

(18) According to the present invention, the pharmaceutically acceptable carrier comprises a solvent selected from the group consisting of water, normal saline, phosphate buffered saline (PBS), aqueous solution containing alcohol, and combinations thereof.

(19) According to the present invention, the medicament can be administered by parenteral routes selected from the group consisting of intraepidermal injection, subcutaneous injection, intradermal injection, intramuscular injection, intravenous injection, and intralesional injection.

(20) According to the present invention, the medicament can be manufactured to an external preparation suitable for topical application to the skin using techniques well known to those skilled in the art, including, but not limited to, emulsion, gel, ointment, cream, patch, liniment, powders, aerosol, spray, lotion, serum, paste, foam, drop, suspension, salve, and bandage.

(21) According to the present invention, the external preparation is prepared by mixing the medicament of the present invention with a base well known to those skilled in the art.

(22) According to the present invention, the base may comprise one or more additives selected from the group consisting of water, alcohols, glycol, hydrocarbons such as petroleum jelly and white petrolatum, wax such as paraffin and yellow wax, preserving agents, antioxidants, surfactants, absorption enhancers, stabilizing agents, gelling agents such as Carbopol® 974P, microcrystalline cellulose and carboxymethylcellulose, active agents, humectants, odor absorbers, fragrances, pH adjusting agents, chelating agents, emulsifiers, occlusive agents, emollients, thickeners, solubilizing agents, penetration enhancers, anti-irritants, colorants, and propellants. The selection and quantity of these additives fall within the scope of professional literacy and routine techniques of those skilled in the art.

Example 1

(23) Preparation of Biomaterial and Evaluation of the Effect of Biomaterial on Regulating Osteoblast-Specific Genes

(24) In an embodiment of the present invention, a 1-50% (w/v) biocompatible polymer solution was prepared first. A protein molecule or a polysaccharide molecule may be used as the biocompatible polymer. When the biocompatible polymer is a protein molecule, a gelatin solution (Sigma-Aldrich) is preferred, wherein the gelatin is obtained from the skin of pigs (G1890 (9000-70-8), Sigma-Aldrich). It can also be replaced by collagen. When the biocompatible polymer is a polysaccharide molecule, the polysaccharide molecule can be hyaluronic acid, alginate, chitosan, or a combination thereof. In this example, the biocompatible polymer is in a form of a colloid, a scaffold, a sphere, a powder, or a film.

(25) Next, 1-50% (w/v) hydroxyapatite (Hap, Sigma-Aldrich, 677418 (12167-74-7)) was added to the gelatin solution, and then metformin (Sigma-Aldrich) (1,1-Dimethylbiguanide hydrochloride, D150959 (1115-70-4), Sigma-Aldrich) was added to the gelatin solution, such that the metformin has a concentration of 50 μM. In this example, hydroxyapatite is an inorganic salt, which can be substituted by tricalcium phosphate (TCP), dicalcium phosphate (DCP), dicalcium phosphate dihydrate (DCPD), tetracalcium phosphate (TTCP), carbonate, nitrate, sulfate, potassium salts, sodium salts, or magnesium salts. In this example, the biocompatible polymer or the inorganic salt has an average size from 1 nm to 1 mm.

(26) In this example, the metformin is a biguanide which is a hypoglycemic drug. Alternatively, the hypoglycemic drug is selected from the group consisting of: insulin, sulfonylurea, meglitinide, thiazolidinedione, an α-Glucosidase inhibitor, a dipeptidyl peptidase 4 (DPP-4) inhibitor, a sodium-glucose transport protein 2 (SGLT2) inhibitor, and cycloset.

(27) 1-50% wt % enzyme cross-linking agent (Ajinomoto) was added, and the resultant mixture was continuously stirred for 24 hours. Thereafter, casting (Nunc™ Cell-Culture Treated Multidishes 24-well plates) and freeze-drying were performed to obtain the biomaterial of the present invention (a solid after drying, and also in a solid form in use), and a microstructure diagram thereof is shown in FIG. 1. The small white dot in FIG. 1 (see white arrows) is the hypoglycemic drug. The two diagrams above and below show different magnifications (the upper is 200× magnification; the lower is 3500× magnification). The upper diagram shows that the pore size is suitable for bone growth, and the lower diagram shows the coating of the hypoglycemic drug. In this example, the enzyme cross-linking agent is a binder, which is crosslinked by an enzyme selected from the group consisting of: transglutaminase, lipase, peptidase, sortase, oxidoreductase, tyrosinase, polyphenoloxidase (PPO), laccase, peroxidase, lysyl oxidase, and amine oxidase.

(28) Mesenchymal stem cells (MSCs) can differentiate into osseous bone, cartilage, adipose and other connective tissues or transdifferentiate into neural cells, liver cells, etc., which are called monoblastic pluripotent stem cells.

(29) Subsequently, mesenchymal stromal cells (MSCs) obtained from patients who need to promote bone regeneration (IRB number 201904070RINA) were cultured, and a control group and an experimental group of cells were prepared. 5% (v/v) biomaterial in the form of MGS microsphere was added to the cells in the experimental group, while the cells in the control group were not added with the biomaterial. After 3, 7, 14, 21, or 28 days of treating the cells, the cell culture was collected and used for gene expression analysis.

(30) In this example, the osteoblast-specific genes used for analysis include alkaline phosphatase (ALPP) gene, runt-related transcription factor 2 (RUNX2) gene, osterix (SP7) gene, osteonectin (SPARC) gene, osteocalcin (BGLAP) gene, and collagen type I alpha 1 (COL1A1) gene.

(31) RNA extraction was performed on the cell culture obtained above using Qiazol (Qiagen, Valencia, Calif.), and random hexamers (Vivantis Inc., California) and reverse transcriptase (Vivantis Cat No: RTPL12) were used to reverse-transcribe the extracted RNA into cDNA. The cDNA was used as a template, primer pairs for amplification of target genes, including ALPP, RUNX2, SP7, SPARC, BGLAP, COL1A, and GAPDH (as an endogenous control group) were used for osteogenic differentiation, and their nucleotide sequences are shown in Table 1. TOOLS 2X SYBR qPCR Mix (Biotools Co., Ltd., Taipei, Taiwan) was applied for real-time RT-PCR using CFX Connect Real-Time PCR Detection System (BioRed, CA, USA) to amplify the target genes.

(32) TABLE-US-00001 TABLE 1 SEQ Target ID gene NO. # Primer name Sequence (5′ --> 3′) ALPP 1 ALPP-F GAGAAGCCGGGACACAGTTC 2 ALPP-R CCTCCTCAACTGGGATGATGC RUNX2 3 RUNX2-F TAGGCGCATTTCAGGTGCTT 4 RUNX2-R GGTGTGGTAGTGAGTGGTGG SP7 5 SP7-F TAGGACTGTAGGACCGGAGC 6 SP7-R CATAGTGAACTTCCTCCTGGGG SPARC 7 SPARC-F ATTGACGGGTACCTCTCCCA 8 SPARC-R GAAAAAGCGGGTGGTGCAAT BGLAP 9 BGLAP-F CTCACACTCCTCGCCCTATTG 10 BGLAP-R GCTTGGACACAAAGGCTGCAC COL1A1 11 COL1A1-F AGAGGTCGCCCTGGAGC 12 COL1A1-R CAGGAACACCCTGTTCACCA GAPDH 13 GAPDH-F AATGGGCAGCCGTTAGGAAA 14 GAPDH-R GCCCAATACGACCAAATCAGAG

(33) PCR parameters were as follows: 95° C. for denaturation (3 min), 40 cycles of 95° C. for 20 s, 60° C. for annealing (30 s), and 72° C. for elongation (30 s). The expression of the target genes was calculated in using glyceraldehyde 3-phosphate dehydrogenase (GAPDH) as an endogenous control, wherein ΔCt=Ct.sub.target gene−Ct.sub.GAPDH, ΔΔCt=ΔCt.sub.test sample−ΔCt.sub.control sample, fold change=2.sup.−ΔΔCt. The control group was internalized (normalized). The control group was made as 1 fold, and the fold change of the experimental group was calculated compared to that of the control group. There is no control group in the presentation of the diagram, only the expression of the experimental group, because the fold of the control group is 1. The results of this example are shown in FIG. 2.

(34) FIG. 2 is a data diagram showing the effect of the biomaterial of the present invention (using insulin as a hypoglycemic drug component) on regulating osteoblast-specific genes on the 7th, 14th, 21th, and 28th days after treating cells. As shown in FIG. 2, after normalization in the control group, the expression levels of osteoblast-specific genes (including ALPP, RUNX2, SP7, SPARC, BGLAP and COL1A1 genes) were upregulated on the 7th, 14th, 21th, and 28th days after the mesenchymal stem cells (MSCs) were treated with the biomaterial of the present invention (using insulin as a hypoglycemic drug component).

Example 2

(35) Evaluation of Effect of Biomaterial on Promoting Regeneration of Bone Tissues

(36) The surgical procedures were standardized for the creation of in vivo bone defect sites in the rat model. For the in vivo surgical analysis, a total of 27 rats (6-week-old male rats) were obtained from the Center for Laboratory Animals, College of Medicine, National Taiwan University and anesthetized with a 1:2 concentration of Zoletil and Rompum (1 mL/kg) via intraperitoneal injection. A single bone defect was created at the ulna in an aseptic surgical environment. A bone defect of 5 mm was generated from the middle of ulna (this is a bone defect that is more severe than general bone defects). The bone defects were then filled with the biomaterial of the present invention (using metformin as a hypoglycemic drug component). A bone defect without any filling material as a control. After the implantation of the bone graft, the wound closure was performed using 5-0 absorbable sutures. A computed tomography (CT) scan was performed 4 weeks after implantation of the bone graft, and the experimental result is shown in FIG. 3.

(37) FIG. 3 is a computed tomography diagram showing the effect of the biomaterial of the present invention on promoting regeneration of bone tissues. As shown in FIG. 3, compared with the control group (upper), the experimental group (lower) using the biomaterial of the present invention (with metformin as a hypoglycemic drug component) as the bone filling can significantly promote regeneration of bone tissues.

(38) In summary, the biomaterial of the present invention has the effect on regulating osteoblast-specific genes (including alkaline phosphatase (ALPP) gene, runt-related transcription factor 2 (RUNX2) gene, osterix (SP7) gene, osteonectin (SPARC) gene, osteocalcin (BGLAP) gene, and collagen type I alpha 1 (COL1A1) gene) to promote tissue regeneration (such as regeneration of bone tissues), and human experiments are also proved effective.

(39) Although the present invention has been described with reference to the preferred embodiments, it will be apparent to those skilled in the art that a variety of modifications and changes in form and detail may be made without departing from the scope of the present invention defined by the appended claims.